Big biotech, Big pharma, Biotech, Partnering, Pharma

Genentech pharma delas Immunocore for $330 million cancer and viral targets

Posted on 28 June 2013

Tags: , , ,

Immunocore has entered into pharma deals involving a collaborative R&D and licensing agreement with Genentech for the discovery and development of multiple novel cancer targets using Immunocore’s ImmTAC technology.

Genentech, the big pharma and big biotech company taking part in the pharma deals, is a member of the Roche Group,

Under the terms of the pharma deals agreement, Immunocore will receive an initiation fee of between $10 and $20 million per programme and is eligible to receive in excess of $300 million in development and commercial milestone payments for each target programme and significant tiered royalties as part of the pharma deals.

Immunocore has created a world-leading platform of bi-specific biological drugs, called ImmTACs, which exploit the power of T Cell Receptors to recognise intracellular changes that occur during cancer or viral infection, which will be utilised in the pharma deals.

This unique recognition ability of TCRs sets them apart from traditional antibody-based therapies that can only recognise changes on the surface of cells, and provides, for the first time, the ability to develop extremely potent targeted therapies for cancers that are currently poorly served.

A particular feature is that the ImmTACs, to be used in the pharma deals, can be directed to target and destroy only the cancerous cells, avoiding damage to healthy cells.


Report: Partnering Deals and Alliances with Genentech

Report: Partnering Deals and Alliances with Roche

Report: Oncology Partnering Terms and Agreements

Report: Infectives Partnering Terms and Agreements

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply